BioSpace News Archive

The award recognises Medherant’s rapid progress and innovation in the development of next-generation transdermal drug delivery patches.

The company ntends to use the cash from the offering for the advancement of clinical programs, product development, and for working capital and other general corporate purposes.

The new initiative will firstly prioritize gastrointestinal (GI) diseases and endocrine disorders.

Senior executives from Voyager Therapeutics’ scientific, clinical and management team provided the highlights.

Corium’s fiscal year ends on September 30.

Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science.

The study results reconfirm that Myring is bioequivalent to Nuvaring, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers.

A new real-world analysis of adults with type 2 diabetes and established CVD shows adult patients who initiated therapy with INVOKANA or another SGLT2i had a 43 percent reduced risk for ACM and hospitalization for HHF after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an ITT approach.

The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2017 financial results and provide a business update.

All comparative amounts in brackets refer to the outcome of InDex overall activities during the corresponding period 2016.